drugset / Trial / NCT02771093

An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus

NCT02771093

Phase 4 Completed 27 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once daily for 4 weeks on glycemic variation in patients with type 2 diabetes mellitus using continuous glucose monitoring (CGM).

Timeline

Start
2016-09-08
Primary completion
2017-04-27
Completion
2017-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg Oral
Subject Trelagliptin Small molecule 100 mg Oral